drugset / Trial / NCT02660281
URMC Related Haplo-identical Donor BMT
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
Timeline
- Start
- 2015-10
- Primary completion
- 2019-10-28
- Completion
- 2021-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 14.5 mg/kg | — |
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 50 mg/kg | — |
| Subject | Busulfan | Small molecule | 130 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 14.5 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Subject | Fludarabine | Small molecule | 25 mg/m2 | — |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |
| Subject | Thiotepa | Other / unclassified | 8 mg/kg | — |